Medical Imaging—Editorial
Prognostic role of FDG-PET/CT in differentiated thyroid carcinoma: Where are we now?
Giorgio Treglia,
Luca Giovanella,
Corresponding Author
Giorgio Treglia
Department of Nuclear Medicine, Thyroid and PET/CT Center, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Correspondence
Dr Giorgio Treglia, Department of Nuclear Medicine and PET/CT Center, Oncology Institute of Southern Switzerland, via Ospedale, 12, Bellinzona, CH-6500, Switzerland.
Email: [email protected]
Search for more papers by this authorLuca Giovanella
Department of Nuclear Medicine, Thyroid and PET/CT Center, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Search for more papers by this authorGiorgio Treglia,
Luca Giovanella,
Corresponding Author
Giorgio Treglia
Department of Nuclear Medicine, Thyroid and PET/CT Center, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Correspondence
Dr Giorgio Treglia, Department of Nuclear Medicine and PET/CT Center, Oncology Institute of Southern Switzerland, via Ospedale, 12, Bellinzona, CH-6500, Switzerland.
Email: [email protected]
Search for more papers by this authorLuca Giovanella
Department of Nuclear Medicine, Thyroid and PET/CT Center, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Search for more papers by this authorG Treglia MD; L Giovanella MD.
Conflicts of interest: None.
References
- 1Schönberger J, Rüschoff J, Grimm D et al. Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid 2002; 12: 747–754.
- 2Piccardo A, Puntoni M, Bertagna F et al. 18F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study. Eur J Nucl Med Mol Imaging 2014; 41: 1482–1491.
- 3Pace L, Klain M, Salvatore B et al. Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients. Clin Nucl Med 2015; 40: 111–115.
- 4Alzahrani AS, Abouzied ME, Salam SA et al. The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer. Eur J Endocrinol 2008; 158: 683–689.
- 5Qiu ZL, Xue YL, Song HJ, Luo QY. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Nucl Med Commun 2012; 33: 1232–1242.
- 6Wang W, Larson SM, Fazzari M et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000; 85: 1107–1113.
- 7Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91: 498–505.
- 8Deandreis D, Al Ghuzlan A, Leboulleux S et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer 2011; 18: 159–169.
- 9Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med 2012; 37: 953–959.
- 10Schreinemakers JM, Vriens MR, Munoz-Perez N et al. Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management. World J Surg Oncol 2012; 10: 192.
- 11Nagamachi S, Wakamatsu H, Kiyohara S et al. Comparison of diagnostic and prognostic capabilities of 18F-FDG-PET/CT, 131I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer. Jpn J Radiol 2011; 29: 413–422.
- 12Salvatore B, Paone G, Klain M et al. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation. Q J Nucl Med Mol Imaging 2008; 52: 2–8.
- 13Bogsrud TV, Hay ID, Karantanis D et al. Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies. Nucl Med Commun 2011; 32: 245–251.
- 14Marcus C, Antoniou A, Rahmim A, Ladenson P, Subramaniam RM. Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival. J Med Imaging Radiat Oncol 2015; 59: 281–288.
- 15Treglia G, Annunziata S, Muoio B, Salvatori M, Ceriani L, Giovanella L. The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: an overview. Int J Endocrinol 2013; 2013: 856189.
Citing Literature
